ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo

Brian Spencer, Sharareh Emadi, Paula Desplats, Simona Eleuteri, Sarah Michael, Kori Kosberg, Jay Shen, Edward Rockenstein, Christina Patrick, Anthony Adame, Tania Gonzalez, Michael Sierks, Eliezer Masliah

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Parkinson's disease and dementia with Lewy bodies are neurodegenerative disorders characterized by accumulation of α-synuclein (α-syn). Recently, single-chain fragment variables (scFVs) have been developed against individual conformational species of α-syn. Unlike more traditional monoclonal antibodies, these scFVs will not activate or be endocytosed by Fc receptors. For this study, we investigated an scFV directed against oligomeric α-syn fused to the LDL receptor-binding domain from apolipoprotein B (apoB). The modified scFV showed enhanced brain penetration and was imported into neuronal cells through the endosomal sorting complex required for transport (ESCRT) pathway, leading to lysosomal degradation of α-syn aggregates. Further analysis showed that the scFV was effective at ameliorating neurodegenerative pathology and behavioral deficits observed in the mouse model of dementia with Lewy bodies/Parkinson's disease. Thus, the apoB modification had the effect of both increasing accumulation of the scFV in the brain and directing scFV/α-syn complexes for degradation through the ESCRT pathway, leading to improved therapeutic potential of immunotherapy.

Original languageEnglish (US)
Pages (from-to)1753-1767
Number of pages15
JournalMolecular Therapy
Volume22
Issue number10
DOIs
StatePublished - Jan 1 2014

Fingerprint

Endosomal Sorting Complexes Required for Transport
Synucleins
Single-Chain Antibodies
Apolipoproteins B
Parkinson Disease
Lewy Body Disease
Fc Receptors
LDL Receptors
Brain
Endocytosis
Neurodegenerative Diseases
Immunotherapy
Dementia
Monoclonal Antibodies
Pathology
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Spencer, B., Emadi, S., Desplats, P., Eleuteri, S., Michael, S., Kosberg, K., ... Masliah, E. (2014). ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Molecular Therapy, 22(10), 1753-1767. https://doi.org/10.1038/mt.2014.129

ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. / Spencer, Brian; Emadi, Sharareh; Desplats, Paula; Eleuteri, Simona; Michael, Sarah; Kosberg, Kori; Shen, Jay; Rockenstein, Edward; Patrick, Christina; Adame, Anthony; Gonzalez, Tania; Sierks, Michael; Masliah, Eliezer.

In: Molecular Therapy, Vol. 22, No. 10, 01.01.2014, p. 1753-1767.

Research output: Contribution to journalArticle

Spencer, B, Emadi, S, Desplats, P, Eleuteri, S, Michael, S, Kosberg, K, Shen, J, Rockenstein, E, Patrick, C, Adame, A, Gonzalez, T, Sierks, M & Masliah, E 2014, 'ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo', Molecular Therapy, vol. 22, no. 10, pp. 1753-1767. https://doi.org/10.1038/mt.2014.129
Spencer, Brian ; Emadi, Sharareh ; Desplats, Paula ; Eleuteri, Simona ; Michael, Sarah ; Kosberg, Kori ; Shen, Jay ; Rockenstein, Edward ; Patrick, Christina ; Adame, Anthony ; Gonzalez, Tania ; Sierks, Michael ; Masliah, Eliezer. / ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. In: Molecular Therapy. 2014 ; Vol. 22, No. 10. pp. 1753-1767.
@article{491db558fa3f4036856ac9169c245d0c,
title = "ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo",
abstract = "Parkinson's disease and dementia with Lewy bodies are neurodegenerative disorders characterized by accumulation of α-synuclein (α-syn). Recently, single-chain fragment variables (scFVs) have been developed against individual conformational species of α-syn. Unlike more traditional monoclonal antibodies, these scFVs will not activate or be endocytosed by Fc receptors. For this study, we investigated an scFV directed against oligomeric α-syn fused to the LDL receptor-binding domain from apolipoprotein B (apoB). The modified scFV showed enhanced brain penetration and was imported into neuronal cells through the endosomal sorting complex required for transport (ESCRT) pathway, leading to lysosomal degradation of α-syn aggregates. Further analysis showed that the scFV was effective at ameliorating neurodegenerative pathology and behavioral deficits observed in the mouse model of dementia with Lewy bodies/Parkinson's disease. Thus, the apoB modification had the effect of both increasing accumulation of the scFV in the brain and directing scFV/α-syn complexes for degradation through the ESCRT pathway, leading to improved therapeutic potential of immunotherapy.",
author = "Brian Spencer and Sharareh Emadi and Paula Desplats and Simona Eleuteri and Sarah Michael and Kori Kosberg and Jay Shen and Edward Rockenstein and Christina Patrick and Anthony Adame and Tania Gonzalez and Michael Sierks and Eliezer Masliah",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/mt.2014.129",
language = "English (US)",
volume = "22",
pages = "1753--1767",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo

AU - Spencer, Brian

AU - Emadi, Sharareh

AU - Desplats, Paula

AU - Eleuteri, Simona

AU - Michael, Sarah

AU - Kosberg, Kori

AU - Shen, Jay

AU - Rockenstein, Edward

AU - Patrick, Christina

AU - Adame, Anthony

AU - Gonzalez, Tania

AU - Sierks, Michael

AU - Masliah, Eliezer

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Parkinson's disease and dementia with Lewy bodies are neurodegenerative disorders characterized by accumulation of α-synuclein (α-syn). Recently, single-chain fragment variables (scFVs) have been developed against individual conformational species of α-syn. Unlike more traditional monoclonal antibodies, these scFVs will not activate or be endocytosed by Fc receptors. For this study, we investigated an scFV directed against oligomeric α-syn fused to the LDL receptor-binding domain from apolipoprotein B (apoB). The modified scFV showed enhanced brain penetration and was imported into neuronal cells through the endosomal sorting complex required for transport (ESCRT) pathway, leading to lysosomal degradation of α-syn aggregates. Further analysis showed that the scFV was effective at ameliorating neurodegenerative pathology and behavioral deficits observed in the mouse model of dementia with Lewy bodies/Parkinson's disease. Thus, the apoB modification had the effect of both increasing accumulation of the scFV in the brain and directing scFV/α-syn complexes for degradation through the ESCRT pathway, leading to improved therapeutic potential of immunotherapy.

AB - Parkinson's disease and dementia with Lewy bodies are neurodegenerative disorders characterized by accumulation of α-synuclein (α-syn). Recently, single-chain fragment variables (scFVs) have been developed against individual conformational species of α-syn. Unlike more traditional monoclonal antibodies, these scFVs will not activate or be endocytosed by Fc receptors. For this study, we investigated an scFV directed against oligomeric α-syn fused to the LDL receptor-binding domain from apolipoprotein B (apoB). The modified scFV showed enhanced brain penetration and was imported into neuronal cells through the endosomal sorting complex required for transport (ESCRT) pathway, leading to lysosomal degradation of α-syn aggregates. Further analysis showed that the scFV was effective at ameliorating neurodegenerative pathology and behavioral deficits observed in the mouse model of dementia with Lewy bodies/Parkinson's disease. Thus, the apoB modification had the effect of both increasing accumulation of the scFV in the brain and directing scFV/α-syn complexes for degradation through the ESCRT pathway, leading to improved therapeutic potential of immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84926209020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926209020&partnerID=8YFLogxK

U2 - 10.1038/mt.2014.129

DO - 10.1038/mt.2014.129

M3 - Article

C2 - 25008355

AN - SCOPUS:84926209020

VL - 22

SP - 1753

EP - 1767

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 10

ER -